Provider: View Press Release
Type: Link
Title: GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma | GSK
Description: Trial unblinded early at an interim analysis based on Independent Data Monitoring Committee recommendation
Provider: View Press Release
Type: Link
Title: ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges | GSK
Description: The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at CROI.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses | GSK
Description: GSK announced the company’s first step towards delivering ultra long-acting injectable HIV treatment.
Provider: View Press Release
Type: Link
Title: GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director | GSK
Description: GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director.
Provider: View Press Release
Type: Link
Title: Statement: Zantac (ranitidine) litigation | GSK
Description: GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV | GSK
Description: Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.